Small Molecules

31 May 2019 Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis
30 May 2019 Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
30 May 2019 Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
30 May 2019 Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
30 May 2019 BioTheryX Announces FDA approval of IND Application to Initiate Phase I Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia
30 May 2019 Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
29 May 2019 MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
29 May 2019 Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
29 May 2019 KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop
29 May 2019 UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration
29 May 2019 FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
28 May 2019 Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy
26 May 2019 FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
26 May 2019 Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures
26 May 2019 FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
24 May 2019 Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference
24 May 2019 Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
24 May 2019 Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
24 May 2019 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
24 May 2019 Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression
22 May 2019 Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
21 May 2019 Debiopharm Expands its Immuno-Oncology Development Program for Debio 1143, with the First IAP Inhibitor/Nivolumab Combination Trial
21 May 2019 BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
21 May 2019 Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
21 May 2019 Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up